Engineering Commercial Readiness: Aligning Scale, Geography, and Launch Risk
June 23, 2026
BioProcess Theatre
Type: BioProcess Session
As biologics programs approach Phase III and BLA submission, manufacturing decisions become strategic inflection points. Commercial geography, inspection exposure, and infrastructure resilience now directly influence launch timing and long-term supply continuity. This session explores how sponsors can structure scale-up, engineering batches, and tech transfer within commercial-intent systems to reduce switching risk and prevent late-stage disruption. Drawing on real-world expansion and operational design considerations, the discussion highlights how disciplined scale-up strategy and U.S.-anchored manufacturing can serve as controlled bridges from development through PPQ and commercial launch.
Speakers
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}